Serum CA 242: The search for a valid marker of pancreatic cancer

Clinical Chemistry and Laboratory Medicine

Volumn 36, Issue 3, 1998, Pages 179-184

  Ventrucci, Maurizio ^b   Ubalducci, Giuseppina Margaret ^c   Cipolla, Antonio ^c   Panella, Maria Antonietta ^c   Ligabue, Amedeo ^a  

^a Laboratorio Centralizzato   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c NONE

Author keywords

CA 242; Chronic pancreatitis; Pancreatic cancer; Tumour markers

Indexed keywords

CA 19-9 ANTIGEN; CA 242 ANTIGEN; CA 50 ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CHOLESTASIS; CHRONIC PANCREATITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FLUOROIMMUNOASSAY; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; METASTASIS; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

EID: 0031948770     PISSN: 14346621     EISSN: None     Source Type: Journal    
DOI: 10.1515/CCLM.1998.033     Document Type: Article

References (18)

1. Röthlin M, Metzger U, Joller H, Largiadèr F. Die Tumor-marker CA 19.9, CA 50 und CEA in der Differentialdiagnose des Pankreaskarzinoms. Schweiz Med Wochenschr 1988; 118:924-9.
2. Schmiegel W. Tumor markers in pancreatic cancer: current concepts. Hepatogastroenterology 1989; 36:446-9.
3. Paganuzzi M, Onetto M, Marroni P, Barone D, Conio M, Aste H, et al. CA 19.9 and CA 50 in benign and malignant pancreatic and biliary diseases. Cancer 1988; 61:2100-8.
4. Haglund C, Roberts PJ, Kuusela P, Jalanko H. Tumour markers in pancreatic cancer. Scand J Gastroenterol Suppl 1986; 126:75-8.
5. Lindholm L, Johansson C, Jansson EL, Hallberg C, Nilsson O. An immuno-radiometric assay (IRMA) for the CA 50 antigen. In: Holmgren J, editor. Tumour marker antigen. Lund Sweden: Studentlitteratur, 1985: 123-33.
6. Cubilla AL, Fitzgerald PS. Surgical pathology of tumours of the exocrine pancreas. In: Moussa AR, editor. Tumours of the pancreas. Baltimore: Williams and Wilkins, 1980:159-93.
7. Robertson EA, Zweig MH. Use of receiver operating characteristic curves to evaluate the clinical performance of analytical systems. Clin Chem 1981; 27:1569-74.
8. Ashley SW, Reber HA. Surgical management of exocrine pancreatic cancer. In: Go VLW, DiMagno EP, Gardner JD, Lebenthal E, Reber HA, Scheele GA, editors. The pancreas: biology, pathobiology, and disease. 2nd ed. New York: Raven Press, 1993:913-29.
9. Sakahara H, Endo K, Nakajima K, Nakashima T, Koizumi M, Ohta H, et al. Serum CA 19.9 concentrations and computed tomography findings in patients with pancreatic carcinoma. Cancer 1986; 57:1324-6.
10. Gullo L. CA 19-9: the Italian experience. Pancreas 1994; 9:717-9.
11. Nilsson O, Jansson EL, Johansson C, Lindholm L. CA 242: a novel tumor-associated carbohydrate antigen with increased tumor specificity and sensitivity. J Tumor Marker Oncol 1988; 3:314.
12. Johansson C, Nilsson O, Lindholm L. Comparison of serological expression of different epitopes on the CA 50-carrying antigen CanAg. Int J Cancer 1991; 48:757-63.
13. Nilsson O, Johansson C, Glimelius B, Persson B, Nørgaard-Pedersen B, Andrén-Sandberg A, et al. Sensitivity and specificity of CA 242 in gastrointestinal cancer. A comparison with CEA, CA 50 and CA19-9. Br J Cancer 1992; 65:215-21.
14. Röthlin MA, Joller H, Largiadèr F. CA 242 is a new tumor marker for pancreatic cancer. Cancer 1993; 71 (3):701-7.
15. Pasanen PA, Eskelinen M, Partanen K, Pikkarainen P, Penttilä I, Alhava E. A prospective study of serum tumour markers carcinoembryonic antigen, carbohydrate antigens 50 and 242, tissue polypeptide antigen and tissue polypeptide specific antigen in the diagnosis of pancreatic cancer with special reference to multivariate diagnostic score. Br J Cancer 1994; 69:562-5.
16. Pezzilli R, Billi P, Platè L, Laudadio MA, Sprovieri G. Serum CA 242 in pancreatic cancer. Comparison with CA 19-9 and CEA. Ital J Gastroenterol 1995; 27:296-9.
17. Furuya N, Kawa S, Hasebe O, Tokoo M, Mukawa K, Maejima S, et al. Comparative study of CA242 and CA19-9 in chronic pancreatitis. Br J Cancer 1996; 73:372-6.
18. Pålsson B, Masson P, Andrén-Sandberg Å. The influence of cholestasis on CA 50 and CA 242 in pancreatic cancer and benign biliopancreatic diseases. Scand J Gastroenterol 1993; 28:981-7.